Skip to main
LXEO

LXEO Stock Forecast & Price Target

LXEO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lexeo Therapeutics is a promising genetic medicine company with a portfolio of programs focused on addressing cardiovascular diseases such as Friedreich ataxia, cardiomyopathy, and arrhythmogenic cardiomyopathy. Its lead candidate LX2006 has shown positive results in clinical trials and could potentially generate significant sales in the future. Despite potential challenges in clinical, financing, regulatory, and commercialization areas, the company is well-positioned with its management's optimization strategies, collaborations with research institutions, and strong pipeline programs.

Bears say

Lexeo Therapeutics is facing a negative outlook due to several factors. While the recent acquisition of Mantle Therapeutics broadens the company's portfolio and adds potential for CNS targeting, the preclinical programs from the acquisition face uncertainties and limitations in the commercial landscape for Friedrich's Ataxia. Additionally, competition in the market from other genetic medicine companies may hinder the potential impact of Lexeo's lead assets, LX2006 and LX1001. There are also potential risks in the regulatory landscape and challenges in commercialization, resulting in a limited market for the company's products. Overall, these factors could impede the company's growth and decrease its value in the market.

LXEO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lexeo Therapeutics Inc (LXEO) Forecast

Analysts have given LXEO a Strong Buy based on their latest research and market trends.

According to 7 analysts, LXEO has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lexeo Therapeutics Inc (LXEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.